← Literature

Into the Light: Afamelanotide and the Treatment of Erythropoietic Protoporphyria in the United States.

observational • 2023 • ID: 37683058

Moderate Confidence Observational

Primary source: [Open]

Linked compounds: melanotan-i

Outcomes summary

Questionnaire-based report in U.S. patients receiving afamelanotide for erythropoietic protoporphyria, describing patient-reported improvements in daily life and reduced phototoxicity limitations after treatment in this cohort.

Limitations

Non-randomized, patient-reported outcomes; selection and recall biases; does not replace controlled trial evidence.

Notes

Primary source: PMID 37683058.